Please enable Javascript in your browser.
Back to Buzz Feed
The service is no longer available. Please refer to our RSS help page for information about changes to feeds.
source:
Annals Of Oncology - Oxford Journals - Most Cited
date:
13 Jul 2018
tags:
News , Oncology , Journal
Back to Buzz Feed
Managing multiple ipsilateral breast cancer with potential new surgical options
source:
News-Medical.Net Oncology News Feed
date:
13 Jul 2018
tags:
Oncology , News
A new multi-institutional clinical trial compared outcomes of women with multiple ipsilateral breast cancer, or more than one site of disease in the same breast, who underwent breast-conserving surgery, with outcomes of those who converted to mastectomy.
Visit website
A new multi-institutional clinical trial compared outcomes of women with multiple ipsilateral breast cancer, or more than one site of disease in the same breast, who underwent breast-conserving surgery, with outcomes of those who converted to mastectomy.
Read More
Back to Buzz Feed
Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
source:
Oncology Nurse Advisor - Web Exclusives
date:
13 Jul 2018
tags:
News
Researchers assessed the effect intake levels of folate and other nutrients involved in one-carbon metabolism have on risk of melanoma.
Visit website
Researchers assessed the effect intake levels of folate and other nutrients involved in one-carbon metabolism have on risk of melanoma.
Read More
Back to Buzz Feed
Immunotherapies may increase overall survival in patients with melanoma brain metastases
source:
News-Medical.Net Oncology News Feed
date:
13 Jul 2018
tags:
Oncology , News
Among patients with cutaneous melanoma who had brain metastases (MBM), first-line treatment with a checkpoint inhibitor was associated with a 1.4-fold increase in median overall survival, according to results from a national cohort.
Visit website
Among patients with cutaneous melanoma who had brain metastases (MBM), first-line treatment with a checkpoint inhibitor was associated with a 1.4-fold increase in median overall survival, according to results from a national cohort.
Read More
Back to Buzz Feed
Four-protein biomarker blood test improves lung cancer risk assessment for smokers
source:
News-Medical.Net Oncology News Feed
date:
13 Jul 2018
tags:
Oncology , News
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology.
Visit website
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology.
Read More
Back to Buzz Feed
Deadlier subtype of metastatic prostate cancer found to be common than previously thought
source:
News-Medical.Net Oncology News Feed
date:
13 Jul 2018
tags:
Oncology , News
A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer.
Visit website
A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer.
Read More
Back to Buzz Feed
[News] Growing pains for US proton therapy
source:
The Lancet Oncology - Online First
date:
12 Jul 2018
tags:
News , Oncology , Journal
In 2013, The Lancet Oncology reported on the rapid proliferation of proton beam therapy centres in the USA amid claims that the associated health-care costs were clinically unjustified. Since then, several centres have had lagging patient demand and financial losses, prompting headlines about a possible bubble.
Visit website
In 2013, The Lancet Oncology reported on the rapid proliferation of proton beam therapy centres in the USA amid claims that the associated health-care costs were clinically unjustified. Since then, several centres have had lagging patient demand and financial losses, prompting headlines about a possible bubble.
Read More
Back to Buzz Feed
[Comment] Much ado about robotic versus open radical prostatectomy
source:
The Lancet Oncology - Online First
date:
12 Jul 2018
tags:
News , Oncology , Journal
In their Article in the The Lancet Oncology, Geoffrey Coughlin and colleagues1 provide the functional and oncological results from a trial that randomly assigned 326 men to open radical retropubic prostatectomy or robot-assisted laparoscopic prostatectomy.
Visit website
In their Article in the The Lancet Oncology, Geoffrey Coughlin and colleagues1 provide the functional and oncological results from a trial that randomly assigned 326 men to open radical retropubic prostatectomy or robot-assisted laparoscopic prostatectomy.
Read More
Back to Buzz Feed
[News] Cervical HPV testing versus cytology
source:
The Lancet Oncology - Online First
date:
12 Jul 2018
tags:
News , Oncology , Journal
A new study has concluded that cervical human papillomavirus (HPV) testing results in a reduced probability of grade 3 or worse precancerous lesions at 48 months compared with cytology.
Visit website
A new study has concluded that cervical human papillomavirus (HPV) testing results in a reduced probability of grade 3 or worse precancerous lesions at 48 months compared with cytology.
Read More
Back to Buzz Feed
[Articles] Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study
source:
The Lancet Oncology - Online First
date:
12 Jul 2018
tags:
News , Oncology , Journal
Robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy yielded similar functional outcomes at 24 months. We advise caution in interpreting the oncological outcomes of our study because of the absence of standardisation in postoperative management between the two trial groups and the use of additional cancer treatments. Clinicians and patients should view the benefits of a robotic approach as being largely related to its minimally invasive nature.
Visit website
Robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy yielded similar functional outcomes at 24 months. We advise caution in interpreting the oncological outcomes of our study because of the absence of standardisation in postoperative management between the two trial groups and the use of additional cancer treatments. Clinicians and patients should view the benefits of a robotic approach as being largely related to its minimally invasive nature.
Read More
Back to Buzz Feed
Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
source:
Oncology Nurse Advisor - Web Exclusives
date:
12 Jul 2018
tags:
News
Researchers sought to determine if melanoma risk was associated with oral contraceptive use or if OC users are more likely to have higher exposure to UV light.
Visit website
Researchers sought to determine if melanoma risk was associated with oral contraceptive use or if OC users are more likely to have higher exposure to UV light.
Read More
Back to Buzz Feed
Scientists deliver nano-size packets of genetic code to treat brain tumors in mice
source:
News-Medical.Net Oncology News Feed
date:
12 Jul 2018
tags:
Oncology , News
In a "proof of concept" study, scientists at Johns Hopkins Medicine say they have successfully delivered nano-size packets of genetic code called microRNAs to treat human brain tumors implanted in mice.
Visit website
In a "proof of concept" study, scientists at Johns Hopkins Medicine say they have successfully delivered nano-size packets of genetic code called microRNAs to treat human brain tumors implanted in mice.
Read More
Back to Buzz Feed
Cómo donar su cabello en tres pasos simples
source:
Cancer Net - Blog
date:
12 Jul 2018
tags:
Blog
Spanish
July 12, 2018
Sonja.Hibbs

Donar su cabello es una excelente manera de apoyar a las personas con cáncer que perdieron el suyo. Esto es todo lo que debe saber para empezar.

Visit website
Spanish
July 12, 2018
Sonja.Hibbs

Donar su cabello es una excelente manera de apoyar a las personas con cáncer que perdieron el suyo. Esto es todo lo que debe saber para empezar.

Read More
Back to Buzz Feed
New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers
source:
News-Medical.Net Oncology News Feed
date:
12 Jul 2018
tags:
Oncology , News
Ludwig Cancer Research and the Cancer Research Institute announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI (durvalumab) for advanced ovarian and colorectal cancers.
Visit website
Ludwig Cancer Research and the Cancer Research Institute announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI (durvalumab) for advanced ovarian and colorectal cancers.
Read More
Back to Buzz Feed
Immune-Based Therapy May Help When Melanoma Spreads to Brain
source:
Cancercompass.Com - Top Stories
date:
12 Jul 2018
tags:
News
Back to Buzz Feed
Health Tip: If You're 45 or Older, Get Screened for Colorectal Cancer
source:
Cancercompass.Com - Top Stories
date:
12 Jul 2018
tags:
News
Back to Buzz Feed
Competing Risks in Older Patients With Cancer: A Systematic Review of Geriatric Oncology Trials
source:
Journal Of National Cancer Institute - Early News
date:
12 Jul 2018
tags:
News , Journal
Abstract
Background
It is increasingly recognized that older adults with cancer represent a diverse cohort of patients and that other comorbidities may have an equal impact on survival and quality of life as any diagnosis of malignancy. Competing risk has consequently emerged as an important concept in the design and reporting of geriatric oncology trials.
Methods
We performed a systematic review of phase II and III oncology trials for systemic therapy in older patients with solid organ malignancy from the year 2000 until April 30, 2017. Forty-one trials including 7864 patients were identified for evaluation.
Results
Only 15 trials (36.6%) employed disease-related end points to account for death from other causes, and only one study used statistical analysis that addressed competing risk. Seventeen studies (41.5%) of trials included some assessment of comorbidity or frailty. Twenty-one trials (51.2%) included any assessment of quality of life.
Conclusions
This review demonstrates clear areas for improvement for future studies and highlights the need for careful consideration of trial design, data collection, and appropriate statistical methodology for reporting of competing risks in geriatric oncology trials.
Visit website
Abstract
Background
It is increasingly recognized that older adults with cancer represent a diverse cohort of patients and that other comorbidities may have an equal impact on survival and quality of life as any diagnosis of malignancy. Competing risk has consequently emerged as an important concept in the design and reporting of geriatric oncology trials.
Methods
We performed a systematic review of phase II and III oncology trials for systemic therapy in older patients with solid organ malignancy from the year 2000 until April 30, 2017. Forty-one trials including 7864 patients were identified for evaluation.
Results
Only 15 trials (36.6%) employed disease-related end points to account for death from other causes, and only one study used statistical analysis that addressed competing risk. Seventeen studies (41.5%) of trials included some assessment of comorbidity or frailty. Twenty-one trials (51.2%) included any assessment of quality of life.
Conclusions
This review demonstrates clear areas for improvement for future studies and highlights the need for careful consideration of trial design, data collection, and appropriate statistical methodology for reporting of competing risks in geriatric oncology trials.
Read More
Back to Buzz Feed
Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
source:
Oncology Nurse Advisor - Web Exclusives
date:
11 Jul 2018
tags:
News
A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.
Visit website
A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.
Read More
Back to Buzz Feed
Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma
source:
Oncology Nurse Advisor - Web Exclusives
date:
11 Jul 2018
tags:
News
Approval was granted for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.
Visit website
Approval was granted for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.
Read More
Back to Buzz Feed
FDA Approves the Ventana PD-L1 (SP142) Assay for PD L1 Expression in ≥ 5% IC in Urothelial Carcinoma Tissue
source:
ESMO
date:
11 Jul 2018
tags:
News
The test should be used to select patients with locally advanced or metastatic urothelial carcinoma for treatment with atezolizumab
Visit website
The test should be used to select patients with locally advanced or metastatic urothelial carcinoma for treatment with atezolizumab
Read More
Sign Up to Oncology Buzz